Latest Hotspot

Silence Therapeutics' Zerlasiran Shows Promise in Phase 2 Trial for High Lipoprotein(a)

15 March 2024
3 min read

Silence Therapeutics plc, a leading biotech firm dedicated to improving patients' health by developing precisely tailored drugs that target and silence disease-causing mechanisms, disclosed encouraging initial 36-week results from the active ALPACAR-360 phase 2 trial involving zerlasiran (SLN360). The study includes 178 participants who have a starting baseline lipoprotein (Lp) measurement of 125 nmol/L or higher and are also at an elevated risk of experiencing events related to atherosclerotic cardiovascular disease.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Zerlasiran, an siRNA, is engineered to reduce the production level of Lp, a crucial genetic marker linked to cardiovascular ailments estimated to impact roughly one-fifth of the global populace.

Throughout a double-masked, placebo-managed phase, the administration of zerlasiran was carried out subcutaneously in dosages of 300 mg every 16 or 24 weeks, as well as 450 mg every 24 weeks, in individuals presenting an average initial Lp figure close to 215 nmol/L. The outcomes from this period showed a statistically profound drop in Lp levels from the initial baseline when measured against the placebo, enduring up to 36 weeks. Observations included a median Lp decrease of no less than 90% at 36 weeks for administered doses. Throughout this phase, no additional safety issues came to light.

The research, extending over 60 weeks, is still in progress. Researchers will analyze the secondary endpoints, such as changes in baseline Lp levels at weeks 48 and 60 and the possible influence on various fats and lipoproteins.

Steven Romano, MD, the chief of R&D at Silence, expressed optimism about the phase 2 findings, noting their high consistency with those from phase 1 and the potential they indicate for Zerlasiran's effectiveness in treating patients with elevated levels of Lp. Dr. Romano is looking forward to the forthcoming review of the data at 48 weeks and is hopeful about further development of Zerlasiran to combat the pressing health challenge posed by cardiovascular disease.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of March 14, 2024, there are 9 investigational drugs for the lipoprotein target, including 9 indications, 16 R&D institutions involved, with related clinical trials reaching 44, and as many as 3272 patents.

Zerlasiran targets lipoprotein and aims to address cardiovascular diseases and hyperlipoproteinemias. Currently in Phase 2, Zerlasiran is being evaluated for its potential in treating atherosclerosis and related conditions.

图形用户界面, 文本, 应用程序

描述已自动生成

Development of CCR8 Antibodies as a Hot Target for Immuno-Oncology Therapy in Solid Tumors
Development of CCR8 Antibodies as a Hot Target for Immuno-Oncology Therapy in Solid Tumors
15 March 2024
Deciphering CCR8 Activation and Inhibition Mechanisms: Genentech's Findings in Nature Communications.
Read →
Takeda's Phase 2 Results for Anti-CD38 Antibody Mezagitamab (TAK-079) Show Promise in Immune Thrombocytopenia Treatment
Latest Hotspot
3 min read
Takeda's Phase 2 Results for Anti-CD38 Antibody Mezagitamab (TAK-079) Show Promise in Immune Thrombocytopenia Treatment
15 March 2024
Takeda Reveals Encouraging Initial Outcomes of Phase 2 Trial for Mezagitamab (TAK-079), an Emerging Leading Anti-CD38 Monoclonal Antibody, in Treating Primary Immune Thrombocytopenia.
Read →
Expert Tips for Searching Doxepin on Synapse
Drug Insights
2 min read
Expert Tips for Searching Doxepin on Synapse
15 March 2024
Doxepin, the small molecule drug, serves as a cogent therapeutic agent, targeting both the norepinephrine transporter (NET) and serotonin transporter subtype 5 (SERT-5).
Read →
Pfizer Announces Positive Phase III Results for ADCETRIS® in Treating Resistant Large B-cell Lymphoma
Latest Hotspot
3 min read
Pfizer Announces Positive Phase III Results for ADCETRIS® in Treating Resistant Large B-cell Lymphoma
15 March 2024
Pfizer Reveals Favorable Survival Data from Stage III Study of ADCETRIS® for Recurrent/Resistant Large B-cell Lymphoma Treatment.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.